Loading organizations...

GenEdit wants to transform the delivery of gene therapies for the next generation of non-viral, gene editing-based therapeutics. GenEdit’s technology platfor...
Genedit has raised $58.5M across 3 funding rounds.
Genedit was founded in 2016 by Kunwoo Lee (Founder) and Niren Murthy (Founder) and Hyo Min Park (Founder).
Genedit has raised $58.5M in total across 3 funding rounds.
GenEdit aims to revolutionize genetic medicine through innovative therapies that enable targeted delivery of genetic medicines, overcoming existing limitations.
Genedit was founded in 2016 by Kunwoo Lee (Founder) and Niren Murthy (Founder) and Hyo Min Park (Founder).
Genedit has raised $58.5M in total across 3 funding rounds.
Genedit's investors include Bow Capital, Company K Partners, Daily Partners, DCVC Bio, Andrew Adams, IMM Investment, KB Investment, Korea Investment Partners, KTB Network, Sequoia Capital, SK, Timefolio Asset Management.
GenEdit is a biotechnology company focused on transforming gene therapy delivery by developing next-generation, non-viral, gene editing-based therapeutics. Its core product is the NanoGalaxy® delivery platform, a proprietary polymer nanoparticle technology designed to safely and efficiently deliver CRISPR-Cas9 gene editing components to specific cells and tissues. This platform addresses critical challenges in gene therapy, such as targeted delivery, safety, and efficiency, enabling broader treatment options for genetic diseases. GenEdit primarily serves pharmaceutical companies and researchers developing CRISPR-based therapies, aiming to expand the accessibility and effectiveness of genetic medicines. The company has demonstrated growth momentum through strategic partnerships, including a notable collaboration with Sarepta Therapeutics, and has raised over $58 million in funding since its founding[1][2][5].
GenEdit was founded in 2016 by Kunwoo Lee (CEO) and Hyo Min Park (CTO), both Ph.D. graduates from UC Berkeley. The founders leveraged their academic expertise in polymer nanoparticle technology and gene editing to address the longstanding delivery challenges in CRISPR-based therapeutics. The idea emerged from recognizing that while CRISPR gene editing holds immense therapeutic potential, its clinical application was limited by inefficient and unsafe delivery methods. Early traction came from developing the NanoGalaxy® platform, which encapsulates CRISPR ribonucleoproteins (RNPs) in polymer nanoparticles, enabling targeted and efficient gene editing in vivo. This breakthrough positioned GenEdit as a pioneer in non-viral gene delivery systems[2][4][6].
GenEdit operates at the intersection of two major biotech trends: the rise of CRISPR gene editing and the urgent need for safe, scalable delivery systems. The timing is critical as gene editing therapies move from research to clinical application, with delivery technologies being a key bottleneck. Market forces such as increasing investment in genetic medicines, regulatory support for gene therapies, and growing patient demand for treatments of rare genetic diseases favor GenEdit’s platform. By enabling non-viral delivery, GenEdit contributes to safer, more versatile gene therapies, influencing the broader ecosystem by expanding the range of treatable conditions and accelerating the adoption of gene editing technologies[1][2][3].
Looking ahead, GenEdit is poised to advance its internal pipeline of genetic medicines while expanding partnerships to apply its NanoGalaxy® platform across diverse therapeutic areas. Trends such as personalized medicine, improved gene editing tools, and regulatory frameworks supporting gene therapies will shape its trajectory. As delivery remains a critical hurdle in gene editing, GenEdit’s innovations could significantly broaden the impact of genetic medicines, potentially rewriting treatment paradigms for many genetic diseases. Its continued growth and collaborations will likely enhance its influence in the biotech ecosystem, fulfilling its mission to make genetic medicines accessible to a wider patient population[1][2][5].
Key people at Genedit.
Genedit has raised $58.5M across 3 funding rounds. Most recently, it raised $24.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 23, 2024 | $24.0M Series A | ||
| Sep 23, 2021 | $26.0M Series A | Bow Capital, Company K Partners, Daily Partners, DCVC Bio, Andrew Adams, IMM Investment, KB Investment, Korea Investment Partners, KTB Network, Sequoia Capital, SK, Timefolio Asset Management | |
| Dec 11, 2018 | $8.5M Seed | Kiersten Stead, SK | Bow Capital, Sequoia Capital |